AU2016303474B2 - Motile sperm domain containing protein 2 and cancer - Google Patents

Motile sperm domain containing protein 2 and cancer Download PDF

Info

Publication number
AU2016303474B2
AU2016303474B2 AU2016303474A AU2016303474A AU2016303474B2 AU 2016303474 B2 AU2016303474 B2 AU 2016303474B2 AU 2016303474 A AU2016303474 A AU 2016303474A AU 2016303474 A AU2016303474 A AU 2016303474A AU 2016303474 B2 AU2016303474 B2 AU 2016303474B2
Authority
AU
Australia
Prior art keywords
cancer
mospd2
antibody
inhibitor
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016303474A
Other languages
English (en)
Other versions
AU2016303474A1 (en
Inventor
Eyal Breitbart
Itzhak Mendel
Oshrat Propheta-Meiran
Yaniv Salem
Anat SHOHAM
Niva Yacov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImmuneWalk Therapeutics Inc
Original Assignee
Immunewalk Therapeutics Inc
ImmuneWalk Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunewalk Therapeutics Inc, ImmuneWalk Therapeutics Inc filed Critical Immunewalk Therapeutics Inc
Publication of AU2016303474A1 publication Critical patent/AU2016303474A1/en
Application granted granted Critical
Publication of AU2016303474B2 publication Critical patent/AU2016303474B2/en
Assigned to IMMUNEWALK THERAPEUTICS, INC. reassignment IMMUNEWALK THERAPEUTICS, INC. Request for Assignment Assignors: VASCULAR BIOGENICS LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
AU2016303474A 2015-07-31 2016-07-29 Motile sperm domain containing protein 2 and cancer Active AU2016303474B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199571P 2015-07-31 2015-07-31
US62/199,571 2015-07-31
PCT/IB2016/054584 WO2017021857A1 (en) 2015-07-31 2016-07-29 Motile sperm domain containing protein 2 and cancer

Publications (2)

Publication Number Publication Date
AU2016303474A1 AU2016303474A1 (en) 2018-02-01
AU2016303474B2 true AU2016303474B2 (en) 2022-06-16

Family

ID=57942495

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016303474A Active AU2016303474B2 (en) 2015-07-31 2016-07-29 Motile sperm domain containing protein 2 and cancer

Country Status (10)

Country Link
US (2) US20190040150A1 (enExample)
EP (2) EP3328401B1 (enExample)
JP (1) JP6949818B2 (enExample)
CN (1) CN108135933B (enExample)
AU (1) AU2016303474B2 (enExample)
CA (1) CA2991868C (enExample)
ES (1) ES2839456T3 (enExample)
IL (1) IL257260B (enExample)
NZ (1) NZ738875A (enExample)
WO (1) WO2017021857A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991868C (en) 2015-07-31 2025-05-27 Vascular Biogenics Ltd PROTEIN 2 CONTAINING THE MOTILE SPERM DOMAIN AND CANCER
EP3328408B1 (en) 2015-07-31 2020-10-07 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and inflammation
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3093633A1 (en) * 2018-03-13 2019-09-19 Vascular Biogenics Ltd. Bispecific antibodies to mospd2 and t cell- or nk cell-specific molecules
EP3597193A1 (en) * 2018-07-16 2020-01-22 Universitat Autònoma de Barcelona Therapeutic use of afatinib in cancer
CA3191242A1 (en) * 2020-09-10 2022-03-17 Itzhak Mendel Motile sperm domain containing protein 2 antibodies and methods of use thereof
EP4313146A4 (en) * 2021-03-29 2025-04-02 ImmuneWalk Therapeutics, Inc. MOTILE SPERM DOMAIN CONTAINING PROTEIN 2, INTEGRIN BETA2, AND CD63

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526705A (ja) * 2001-12-19 2005-09-08 リサーチ　ディベロップメント　ファンデーション ビタミンｅに基づく化合物のリポソームによる送達方法
JP2006151902A (ja) * 2004-11-30 2006-06-15 Akita Prefecture 癌転移抑制用トリテルペン誘導体及び該トリテルペン誘導体を用いた癌転移抑制用組成物
US20110257034A1 (en) * 2008-10-10 2011-10-20 Cornell University Methods for identifying genes which predict disease outcome for patients with colon cancer
JP2013532700A (ja) * 2010-08-05 2013-08-19 アルピニア・ローダナム・インスティテュート・オブ・フィトファーマシューティカル・サイエンシーズ・アクチェンゲゼルシャフト 癌を治療するための、レチノール、その前駆体または反応性生物および少なくとも１つのカモミール植物からの植物抽出液を含む組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP2004537969A (ja) * 2000-12-08 2004-12-24 インサイト・ゲノミックス・インコーポレイテッド 脂質関連分子
EP1358329A2 (en) * 2001-02-06 2003-11-05 Incyte Genomics, Inc. Lipid-associated molecules
US20040171009A1 (en) * 2001-05-18 2004-09-02 Tang Y. Tom Lipid-associated molecules
WO2002094988A2 (en) * 2001-05-18 2002-11-28 Incyte Genomics, Inc. Lipid-associated molecules
WO2003025150A2 (en) * 2001-09-21 2003-03-27 Incyte Genomics, Inc. Lipid-associated molecules
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US20090137687A1 (en) * 2003-02-28 2009-05-28 Oxigene, Inc. Compositions and Methods With Enhanced Therapeutic Activity
US20070218116A1 (en) 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
KR20110095288A (ko) * 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 산화된 지질 화합물 및 이의 용도
US20120020954A1 (en) 2009-03-30 2012-01-26 Anat Achiron Methods of predicting clinical course and treating multiple sclerosis
CA2765145A1 (en) 2009-06-15 2010-12-23 Cardiodx, Inc. Determination of coronary artery disease risk
US20110311616A1 (en) 2010-06-17 2011-12-22 Jeff Smith Targeting tumor associated macrophages using bisphosphonate-loaded particles
DE102011005235B4 (de) 2011-03-08 2017-05-24 Sirs-Lab Gmbh Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
WO2012121679A1 (en) * 2011-03-09 2012-09-13 Agency For Science, Technology And Research Method of modulating phenotype of a renal cell cancer-associated monocyte or macrophage
CN104066706B (zh) * 2011-12-12 2017-12-19 脉管生物生长有限公司 炎症的治疗
CN103592432B (zh) * 2013-10-15 2015-06-03 重庆市公安局 一种免疫磁珠分离精子与上皮细胞混合斑中精子的方法
EP3328408B1 (en) 2015-07-31 2020-10-07 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and inflammation
CA2991868C (en) 2015-07-31 2025-05-27 Vascular Biogenics Ltd PROTEIN 2 CONTAINING THE MOTILE SPERM DOMAIN AND CANCER
CA3191242A1 (en) 2020-09-10 2022-03-17 Itzhak Mendel Motile sperm domain containing protein 2 antibodies and methods of use thereof
EP4313146A4 (en) 2021-03-29 2025-04-02 ImmuneWalk Therapeutics, Inc. MOTILE SPERM DOMAIN CONTAINING PROTEIN 2, INTEGRIN BETA2, AND CD63

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526705A (ja) * 2001-12-19 2005-09-08 リサーチ　ディベロップメント　ファンデーション ビタミンｅに基づく化合物のリポソームによる送達方法
JP2006151902A (ja) * 2004-11-30 2006-06-15 Akita Prefecture 癌転移抑制用トリテルペン誘導体及び該トリテルペン誘導体を用いた癌転移抑制用組成物
US20110257034A1 (en) * 2008-10-10 2011-10-20 Cornell University Methods for identifying genes which predict disease outcome for patients with colon cancer
JP2013532700A (ja) * 2010-08-05 2013-08-19 アルピニア・ローダナム・インスティテュート・オブ・フィトファーマシューティカル・サイエンシーズ・アクチェンゲゼルシャフト 癌を治療するための、レチノール、その前駆体または反応性生物および少なくとも１つのカモミール植物からの植物抽出液を含む組成物

Also Published As

Publication number Publication date
EP3328401B1 (en) 2020-10-14
ES2839456T3 (es) 2021-07-05
US20210095044A1 (en) 2021-04-01
CA2991868C (en) 2025-05-27
JP2018527333A (ja) 2018-09-20
IL257260A (en) 2018-03-29
JP6949818B2 (ja) 2021-10-13
US11945875B2 (en) 2024-04-02
CN108135933A (zh) 2018-06-08
CN108135933B (zh) 2022-04-29
EP3735977A1 (en) 2020-11-11
EP3328401A1 (en) 2018-06-06
EP3328401A4 (en) 2019-03-20
HK1254515A1 (en) 2019-07-19
US20190040150A1 (en) 2019-02-07
CA2991868A1 (en) 2017-02-09
NZ738875A (en) 2023-06-30
WO2017021857A1 (en) 2017-02-09
AU2016303474A1 (en) 2018-02-01
IL257260B (en) 2022-09-01

Similar Documents

Publication Publication Date Title
US11945875B2 (en) Motile sperm domain containing protein 2 and cancer
ES2717908T3 (es) Anticuerpos S100A4 y usos terapéuticos de los mismos
WO2018053643A1 (en) Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence
JPWO2016133059A1 (ja) Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
AU2004261260B2 (en) Compositions and methods for restoring sensitivity to treatment with HER2 antagonists
US11136383B2 (en) Methods and compositions for modulaton of transforming growth factor beta-regulated functions
AU2019235652B2 (en) Bispecific antibodies to MOSPD2 and T cell- or NK cell-specific molecules
AU2016303472B2 (en) Motile sperm domain containing protein 2 and inflammation
US20210087247A1 (en) Mps peptides and use thereof
KR20240110556A (ko) Her3 항원-결합 분자를 사용한 암의 치료 및 예방
HK40041339A (en) Motile sperm domain containing protein 2 and cancer
HK1254515B (en) Motile sperm domain containing protein 2 and cancer
WO2011119524A1 (en) Novel targets for regulation of angiogenesis
WO2024120484A1 (en) Antibodies against edil3 and methods of use thereof
GB2631308A (en) Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups
Martin Modulation of System x c-Mediated Glutamate Release in Glioblastoma Multiforme via the Extracellular Matrix: The Agony and the Xctasy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: IMMUNEWALK THERAPEUTICS, INC.

Free format text: FORMER OWNER(S): VASCULAR BIOGENICS LTD.